Neurons are specialized cells that are fundamental to brain function and the nervous system. They are responsible for transmitting and processing information through electrical and chemical signals. Neurons work together to form complex networks, enabling various cognitive functions and behaviors.
The collective activity of billions of interconnected neurons forms intricate neural networks in the brain. These networks allow for the processing and integration of sensory information, motor control, memory formation, learning, and various other cognitive functions. Aging and other environmental factors raise neuroinflammation. We believe when Neuroinflammation increases, cognitive function decreases, leading to various neurodegenerative diseases.
We are exclusively using a powerful platform that creates new therapeutic options that inhibit USP30, Lowering Neuroinflammation
Our Goal is Simple: Lower Neuroinflammation
USP30
USP30 (scissors) is an enzyme that plays a role in the regulation of cellular processes through the removal of ubiquitin molecules from target proteins.
Mitochondria (green structure) is an important part of the cellular network in your body. As cells in your body age, mitochondria grow tags. These tags are removed by USP30. A healthy person naturally produces and regulates USP30. With age and disease, USP30 activity increases excessively leading to too many tags being cut. If USP30 isn’t regulated properly then too many tags are cut leading to cell death and neuroinflammation.
This build up of dead cells and neuroinflammation may lead to Alzheimer’s disease, Parkinson’s disease or ALS (Amyotrophic lateral sclerosis)
TECHNOLOGY
By blocking these overactive scissors, our technology properly regulates USP30 that would otherwise excessively cut mitochondria tags.
When tags are kept in place, the body has the ability to remove defective and old mitochondria on its own.
Less defective and dead cells in the brain lowers neuroinflammation and can lead to a healthier outcome for the patient.
OUR FOCUS
Alzheimer’s disease is a chronic neurodegenerative disorder that primarily affects the brain, leading to a progressive decline in memory, thinking skills, and cognitive abilities. It is the most common cause of dementia, a syndrome characterized by a decline in memory and other cognitive functions severe enough to interfere with daily life.
Parkinson’s disease is a neurodegenerative disorder that primarily affects the central nervous system. It is named after James Parkinson, the British physician who first described its symptoms in 1817. Parkinson’s disease is characterized by a progressive loss of dopamine-producing cells in a region of the brain called the substantia nigra.
Amyotrophic lateral sclerosis (ALS), also known as Lou Gehrig’s disease, is a progressive neurodegenerative disorder that affects the nerve cells responsible for controlling voluntary muscle movement. It is characterized by the gradual degeneration and death of motor neurons in the brain and spinal cord. ALS primarily affects the upper motor neurons in the brain and the lower motor neurons in the spinal cord.
OUR LEADERSHIP
Our team consists of of Ph.D. and M.D. veterans with decades of combined experience & expertise in drug discovery, development, and commercialization. We work with trusted industry consultants and leaders to created an effective and efficient research, marketing and sales approach.
David Horn, MD, FACP, FIDSA
CEO & Founder
Dr. Horn has over 30 years of research and clinical expertise in the clinical development. He has held senior positions at Merck, BMS, and Thomas Jefferson University. Recently he has consulted for large medical firms and transitioned into the private startup biotech field.
Dave Jobes, PH.D.
President & Co-Founder
Dr. Jobes has over 25 years of research, clinical and business development expertise. He is an expert in infectious diseases and CNS disorders. He has held executive positions at Applied Biosystems, VaxGen and Presidio. Dave is best described as a business development executive & consultant (>$5OOM in transactions to date)